“…Recent data suggests that competent Th17 immunity is crucial to clearance and protection from invasive pneumococcal disease of the lung. We demonstrate that early influenza infection significantly reduced levels of pneumococcus driven IL-12p70, IL-23 and IL-27 in human monocytes with significant impairment of IL-17A and IFN-γ in HKSP-treated allogeneic mixed lymphocyte cultures. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Routine use of pneumococcal conjugate vaccines (PCVs) in young children has substantially reduced vaccine-type invasive pneumococcal disease (IPD) in the United States and Europe. …”
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Hematopoietic cell transplant (HCT) recipients are at a significantly greater risk for invasive pneumococcal disease than the general population. However, pneumococcal colonization in pediatric HCT recipients has not been widely studied. …”
Enlace del recurso
Enlace del recurso

“…These patients are at increased risk for invasive pneumococcal disease. Functional asplenia in adult patients is often overlooked in patients with severe or recurrent infections caused by polysaccharide encapsulated bacteria. …”
Enlace del recurso
Enlace del recurso

“…BACKGROUND: In 2010, a ten–valent pneumococcal conjugate vaccine (PCV10) was introduced in the routine infant national immunization program in Brazil. Invasive pneumococcal disease (IPD) caused by serotype 19A (Spn19A) increased after the introduction of PCVs in several countries. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Conclusion: In our rural study area, PCV13 introduction did not meet the Malawi Ministry of Health one-year three-dose 90% coverage target, but after 2 years reached levels likely to reduce the prevalence of both invasive and non-invasive paediatric pneumococcal diseases. Better adherence to the PCV13 schedule may reduce pneumococcal disease in younger Malawian children.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: A microsimulation model depicting expected lifetime risks, consequences, and costs of invasive pneumococcal disease (IPD) and CAP was developed. PPV23 effectiveness was based on published literature, and PCV13 effectiveness was based on CAPiTA; all other model parameters were based on published data or secondary sources. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We assessed the incremental cost-effectiveness ratio of PCV13 introduction by integrating two models: an ecological model (a parsimonious, mechanistic model validated with data from post-seven-valent PCV introduction in 13 high-income settings) to predict the effect of PCV on childhood invasive pneumococcal disease, and a decision-tree model to predict a range of clinical presentations and economic outcomes under vaccination and no-vaccination strategies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We evaluated the impact of continued 13-valent pneumococcal conjugate vaccine (PCV13) use in the private market (uptake of 61%) in pediatric invasive pneumococcal disease (pIPD) in Portugal (2012–2015). The most frequently detected serotypes were: 3 (n = 32, 13.8%), 14 (n = 23, 9.9%), 1 (n = 23, 9.9%), 7F (n = 15, 6.4%), 19A (n = 13, 5.6%), 6B and 15B/C (both n = 12, 5.2%), and 24F, 10A and 12B (all with n = 10, 4.3%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Moreover, PCV13 could be useful in preventing pneumococcal disease in Chongqing, China.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The introduction of pneumococcal conjugate vaccines (PCVs) into childhood vaccination programs has reduced carriage of vaccine serotypes and pneumococcal disease. The 10-valent PCV was introduced in Iceland in 2011. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSIONS: Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting; however, to significantly reduce pneumococcal disease in these settings, PCVs with broader serotype coverage and potency to reduce pneumococcal carriage are needed. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In this modelling and cost-effectiveness study, we fitted a dynamic compartmental model of pneumococcal carriage to annual carriage prevalence surveys and invasive pneumococcal disease (IPD) incidence in Kilifi, Kenya. We predicted disease incidence and related mortality for either continuing PCV use beyond 2022, the start of Kenya's transition from Gavi support, or its discontinuation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We use routine hospital admissions data and time-series modelling analysis to estimate the impact of the seven and thirteen valent pneumococcal conjugate vaccines (PCV7 and PCV13) on hospital admissions due to pneumococcal disease in England. METHODS: Hospital admissions for pneumococcal meningitis, bacteraemia and pneumonia between January 1, 2003 and December 31, 2015 were identified from the national Hospital Episode Statistics database for all age groups in England. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…These same populations are at increased risk of pneumococcal disease. In order to maximize the benefits of pneumococcal vaccination, further targeted and tailored interventions to increase PCV13 uptake in these underserved populations are still necessary.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Infectious and communicable disease outcomes included pneumococcal disease/acute pneumonia, Mycobacterium tuberculosis, latent tuberculosis infection, infectious skin conditions and contagious disease reporting to the prison clinic. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Pneumococcal conjugate vaccines have substantially reduced the incidence of invasive pneumococcal disease (IPD); however, the impact of the vaccine on non-vaccine serotypes (NVT) remains unclear. …”
Enlace del recurso
Enlace del recurso

“…Colonization progresses to persistent carriage when S. pneumoniae forms biofilms, a feature required for the development of pneumococcal disease. Nasopharyngeal biofilms are structured with a matrix that includes extracellular DNA (eDNA), which is sourced from the same pneumococci and other bacteria. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Nasopharyngeal carriage of Streptococcus pneumoniae (the pneumococcus) is a precursor to pneumococcal disease. Several host and environmental factors have been associated with pneumococcal carriage, however few studies have examined the relationship between host factors and pneumococcal carriage density. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: To summarize information about invasive pneumococcal disease (IPD) among children in mainland China. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso